A groundbreaking study design has been outlined in a special report published in The Journal of Applied Laboratory Medicine, highlighting the COVID Immunity Study conducted by the American Association for Clinical Chemistry. With the aim of encouraging similar studies by other scientific societies, the report provides a comprehensive overview of the study’s design, operations, and methodology. By sharing this information, the goal is to bridge gaps in infectious disease research and enhance the global response to future pandemics.
The COVID Immunity Study stands as the first scientific investigation led by a professional association that integrates an online health survey, on-site blood collection, off-site testing and analysis, dissemination of SARS-CoV-2 testing outcomes to participants, and sample banking to explore questions surrounding SARS-CoV-2 immunity. These large-scale epidemiological studies play a fundamental role in understanding virus evolution and informing critical public health decisions.
Typically, studies of this magnitude require significant resources and are conducted by government agencies or collaboratively by academic research groups. However, the success of the COVID Immunity Study demonstrates that scientific societies possess the necessary resources and expertise to undertake such extensive epidemiological research.
Moreover, these organizations have the potential to investigate crucial lines of inquiry that might not typically fall within the focus of traditional funding sources. Although various papers focusing on the results of the COVID Immunity Study have been recently published or are currently in progress, this special report delves into the study’s methodology and outlines the unique challenges faced. Its aim is to provide a blueprint for other scientific societies to emulate.
The COVID Immunity Study was predominantly carried out during the 2021 AACC Annual Scientific Meeting in Atlanta. A total of 698 participants provided consent and completed general health and COVID-19 questionnaires prior to their blood being drawn on-site.
A portion of each sample was sent for T-cell function analysis at Quest Diagnostics, while the remaining samples yielded serum and plasma that were stored at Centers for Disease Control and Prevention (CDC) facilities in Atlanta. These samples were made available to the medical and research communities. Successful collaboration between ADLM staff, subject-matter experts like clinical laboratory scientists and immunologists, and state and local health departments was pivotal to the study’s accomplishments.
Throughout the execution of the COVID Immunity Study, the research group encountered various logistical and practical challenges. These included staffing shortages resulting from the ongoing pandemic, the absence of on-site facilities tailored for scientific studies, supply shortages and delays, and the need for a large number of participants willing to donate blood. Although the COVID Immunity Study was skillfully planned and executed within a six-month timeframe, the authors of the report recommend allocating a period of 12 months or longer for future studies, particularly during pandemic conditions.
The American Association for Clinical Chemistry firmly believes that the unique composition of scientific societies positions them favorably to explore pressing questions in their respective fields that may not attract significant interest from traditional research funding sources. By sharing the findings of the COVID Immunity Study, the authors hope to provide a reference and establish a precedent for member-based organizations to contribute to similar scientific investigations in the future.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it